- Home
- EYPT vs PRSU Comparison
EYPT vs PRSU Comparison
Compare EYPT & PRSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | PRSU |
|---|---|---|
| Founded | 1987 | 1926 |
| Country | United States | United States |
| Employees | N/A | 2100 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Business Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | PRSU |
|---|---|---|
| Price | $12.55 | $47.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $31.80 | $31.67 |
| AVG Volume (30 Days) | ★ 941.4K | 200.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $4.85 |
| Revenue Next Year | $3,115.57 | $4.94 |
| P/E Ratio | ★ N/A | $3.45 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.37 | $26.92 |
| 52 Week High | $19.11 | $47.83 |
Technical Indicators
Market Signals| Indicator | EYPT | PRSU |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 70.59 |
| Support Level | $12.58 | $32.34 |
| Resistance Level | $14.73 | N/A |
| Average True Range (ATR) | 0.75 | 1.13 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 48.53 | 93.12 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About PRSU Pursuit Attractions and Hospitality Inc.
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, Iceland and Costa Rica. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.